Constipation is a common, life-threatening, yet preventable condition. Rates of constipation are higher in people with learning disability, and it is widely accepted that people with a learning disability are less likely to recognise and communicate the symptoms of constipation, therefore increasing the risk of serious consequences.

‘Constipation’ is the second module in the programme: ‘Physical Health Issues in People with Intellectual Disability and Mental Health or Behavioural Difficulties.’ It aims to educate professionals to understand the link between constipation and prescribed psychotropic medication. It particularly focuses clozapine-induced gastrointestinal hypomotility (CIGH) and the implications this has on patient safety.

The incidence of cancer among people with a learning disability is comparable with that of the general population. However, deaths from cancer occur at a much younger age, particularly in women and in more deprived groups.

‘Cancer & Learning Disability is the third module in the programme: ‘Physical Health Issues in People with Intellectual Disability and Mental Health or Behavioural Difficulties.’ It aims to improve the management of patients with a learning disability by highlighting the barriers to treatment and focusing on the importance of prevention and detection as well as delivering a patient-focused care and support plan.

People with a learning disability are more likely than people without to have a mental illness that may require treatment with psychotropic medication.

‘Psychotropic Medications in People With An Intellectual Disability’ is the fourth module in the programme: ‘Physical Health Issues in People with Intellectual Disability and Mental Health or Behavioural Difficulties.’ It aims to improve patient care by examining both the reasons why people with an intellectual disability are more likely to be prescribed psychotropic medication as well as the careful monitoring which may be required to minimise the risk of physical health complications.